Literature DB >> 30147133

New Medications in the Treatment of Nonalcoholic Steatohepatitis.

Scot Walker1.   

Abstract

Nonalcoholic fatty liver disease, an accumulation of fat in the liver, is estimated to occur in almost 1 in 5 adults. With 2 of the most common risk factors being obesity and diabetes, its prevalence is growing. Nonalcoholic steatohepatitis is a more severe form of nonalcoholic fatty liver disease. There are currently no approved drugs to treat nonalcoholic steatohepatitis, but several drugs are being developed to treat this disease.

Entities:  

Keywords:  drug information; formulary management/P&T; gastrointestinal disorders

Year:  2018        PMID： 30147133      PMCID： PMC6102782          DOI： 10.1177/0018578718763098

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  8 in total

Review 1.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Authors:  G Musso; M Cassader; F Rosina; R Gambino
Journal:  Diabetologia       Date:  2012-01-27       Impact factor: 10.122

2.  Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.

Authors:  Zobair M Younossi; Munkhzul Otgonsuren; Linda Henry; Chapy Venkatesan; Alita Mishra; Madeline Erario; Sharon Hunt
Journal:  Hepatology       Date:  2015-10-24       Impact factor: 17.425

Review 3.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

Review 4.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 5.  Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.

Authors:  Rotonya M Carr; Amanke Oranu; Vandana Khungar
Journal:  Gastroenterol Clin North Am       Date:  2016-10-13       Impact factor: 3.806

6.  The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.

Authors:  Rifaat Safadi; Fred M Konikoff; Mahmud Mahamid; Shira Zelber-Sagi; Maya Halpern; Tuvia Gilat; Ran Oren
Journal:  Clin Gastroenterol Hepatol       Date:  2014-05-09       Impact factor: 11.382

7.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  Mariana Lazo; Ruben Hernaez; Mark S Eberhardt; Susanne Bonekamp; Ihab Kamel; Eliseo Guallar; Ayman Koteish; Frederick L Brancati; Jeanne M Clark
Journal:  Am J Epidemiol       Date:  2013-05-23       Impact factor: 4.897

8.  The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.

Authors:  Rohit Loomba; Eric Lawitz; Parvez S Mantry; Saumya Jayakumar; Stephen H Caldwell; Hays Arnold; Anna Mae Diehl; C Stephen Djedjos; Ling Han; Robert P Myers; G Mani Subramanian; John G McHutchison; Zachary D Goodman; Nezam H Afdhal; Michael R Charlton
Journal:  Hepatology       Date:  2017-12-26       Impact factor: 17.425
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.